Prognostic value of lymph node ratio in children with wilms tumor: a systematic review and meta-analysis
- 1PICU of Luoyang Maternal and Child Health Hospital
Abstract
Background: Lymph node (LN) involvement is a critical determinant of staging and prognosis in Wilms tumor (WT). However, conventional binary nodal staging (positive vs. negative) is often compromised by significant variability in surgical lymph node sampling. The lymph node ratio (LNR), which integrates metastatic burden and sampling adequacy, has emerged as a potential prognostic alternative. This systematic review and meta-analysis evaluated whether LNR serves as an independent predictor of survival outcomes in children with WT.
Methods: A systematic query of PubMed, MEDLINE, Embase, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov was executed, covering the period from their earliest records through May 10, 2026. Retrospective cohort studies reporting hazard ratios (HRs) or risk ratios (RRs) for survival outcomes based on LNR in children with WT were included. Overall survival (OS) was the primary outcome; 5-year, 10-year, and 20-year OS were secondary outcomes. Prespecified subgroup analyses were performed by LNR cutoff (≥0.40 vs. <0.40).
Results: Six retrospective cohort studies involving 4,190 patients met the inclusion criteria. High LNR was significantly associated with poorer overall survival (HR = 2.10; 95% CI: 1.67–2.64). This prognostic significance persisted across secondary outcomes, including 5-year OS (RR = 1.14; 95% CI: 1.11–1.17), 10-year OS (RR = 1.19; 95% CI: 1.15–1.23), and 20-year OS (RR = 1.14; 95% CI: 1.10–1.19). Subgroup analysis revealed no significant interaction based on the LNR cutoff (P = 0.74). Sensitivity analyses confirmed the robustness and stability of the pooled findings.
Conclusions: Higher LNR appears to be associated with poorer overall survival in children with WT and may serve as a useful prognostic indicator. By accounting for both nodal disease burden and surgical effort, LNR may provide additional prognostic information beyond conventional nodal status. While LNR represents a valuable adjunct for individualized treatment decisions, prospective studies are required to establish standardized clinical cut-offs and integrate LNR into formal risk-adapted protocols.
Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420261396220.
Related
- Prognostic and Clinicopathological Significance of CD74 Expression in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis
- Prognostic value of the preoperative C-reactive protein-to-lymphocyte ratio in patients with non-metastatic clear cell renal cell carcinoma
- Folate Receptor Alpha (FRα/FOLR1) in Cancer: Diagnostic, Prognostic or Predictive Biomarker? A Critical Review of Its Clinical Utility
- Current Evidence on Gene-Based and Epigenetic Therapeutic, Diagnostic, and Prognostic Strategies in Epithelial-Derived Carcinomas: A Scoping Review
- Asparagine Synthetase Deficiency: A Novel ASNS Variant and a Systematic Review of Clinical Phenotypes and Cerebrospinal Fluid Asparagine Levels
BibTeX
@article{dong2026prognostic,
title = {{Prognostic value of lymph node ratio in children with wilms tumor: a systematic review and meta-analysis}},
author = {Junyu Dong and Jingwen Ni and Lele Li and Kenan Fang},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1890109},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1890109/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Prognostic value of lymph node ratio in children with wilms tumor: a systematic review and meta-analysis
AU - Junyu Dong
AU - Jingwen Ni
AU - Lele Li
AU - Kenan Fang
PY - 2026
DA - 2026/10/08
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1890109
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1890109/full
AB - Background: Lymph node (LN) involvement is a critical determinant of staging and prognosis in Wilms tumor (WT). However, conventional binary nodal staging (positive vs. negative) is often compromised by significant variability in surgical lymph node sampling. The lymph node ratio (LNR), which integrates metastatic burden and sampling adequacy, has emerged as a potential prognostic alternative. This systematic review and meta-analysis evaluated whether LNR serves as an independent predictor of survival outcomes in children with WT. Methods: A systematic query of PubMed, MEDLINE, Embase, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov was executed, covering the period from their earliest records through May 10, 2026. Retrospective cohort studies reporting hazard ratios (HRs) or risk ratios (RRs) for survival outcomes based on LNR in children with WT were included. Overall survival (OS) was the primary outcome; 5-year, 10-year, and 20-year OS were secondary outcomes. Prespecified subgroup analyses were performed by LNR cutoff (≥0.40 vs. <0.40). Results: Six retrospective cohort studies involving 4,190 patients met the inclusion criteria. High LNR was significantly associated with poorer overall survival (HR = 2.10; 95% CI: 1.67–2.64). This prognostic significance persisted across secondary outcomes, including 5-year OS (RR = 1.14; 95% CI: 1.11–1.17), 10-year OS (RR = 1.19; 95% CI: 1.15–1.23), and 20-year OS (RR = 1.14; 95% CI: 1.10–1.19). Subgroup analysis revealed no significant interaction based on the LNR cutoff (P = 0.74). Sensitivity analyses confirmed the robustness and stability of the pooled findings. Conclusions: Higher LNR appears to be associated with poorer overall survival in children with WT and may serve as a useful prognostic indicator. By accounting for both nodal disease burden and surgical effort, LNR may provide additional prognostic information beyond conventional nodal status. While LNR represents a valuable adjunct for individualized treatment decisions, prospective studies are required to establish standardized clinical cut-offs and integrate LNR into formal risk-adapted protocols. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420261396220.
SN - 2234-943X
ER -